BioLineRx (BLRX) EBIAT (2023 - 2025)
Historic EBIAT for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$977000.0.
- BioLineRx's EBIAT rose 8321.88% to -$977000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $151000.0, marking a year-over-year increase of 10064.04%. This contributed to the annual value of -$19.3 million for FY2024, which is 6207.47% up from last year.
- Per BioLineRx's latest filing, its EBIAT stood at -$977000.0 for Q3 2025, which was up 8321.88% from $3.9 million recorded in Q2 2025.
- In the past 5 years, BioLineRx's EBIAT ranged from a high of $18.5 million in Q2 2023 and a low of -$17.5 million during Q4 2023
- In the last 3 years, BioLineRx's EBIAT had a median value of -$977000.0 in 2025 and averaged -$3.0 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 9739.01% in 2024, then soared by 83663.79% in 2025.
- BioLineRx's EBIAT (Quarter) stood at -$17.5 million in 2023, then soared by 54.75% to -$7.9 million in 2024, then skyrocketed by 87.69% to -$977000.0 in 2025.
- Its EBIAT was -$977000.0 in Q3 2025, compared to $3.9 million in Q2 2025 and $5.1 million in Q1 2025.